30752-24-0

Basic information

• Product Name: 1-bromo-4-(3-methylbutoxy)benzene
• Synonyms: 1-bromo-4-(3-methylbutoxy)benzene;1-Bromo-4-iso-pentyloxybenzene
• CAS NO: 30752-24-0
• Molecular Formula: C₁₁H₁₅BrO
• Molecular Weight: 243.1402
• Mol File: 30752-24-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 148-150 °C(Press: 20 Torr)
• Appearance: /
• Density: 1.2543 g/cm3
• CAS DataBase Reference: 1-bromo-4-(3-methylbutoxy)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-4-(3-methylbutoxy)benzene(30752-24-0)
• EPA Substance Registry System: 1-bromo-4-(3-methylbutoxy)benzene(30752-24-0)

Safety Data

• Hazardous Substances Data: 30752-24-0(Hazardous Substances Data)

Usage

Chemical structure

A benzene ring with a bromine atom at the 1 position and a 3-methylbutoxy group at the 4 position.

Common uses

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds.

Physical state

Colorless liquid.

Solubility

Insoluble in water.

Odor

Slightly sweet.

Additional uses

Reagent in organic synthesis and solvent in various chemical processes.

Safety precautions

Flammable, may cause skin, eye, and respiratory irritation if not handled properly.

Upstream product

• 106-41-2 4-bromo-phenol 
• 107-82-4 i-pentyl bromide 
• 1129-64-2 isopentyl phenyl ether 

Downstream Products

• 1189543-98-3 2-chloro-5-[4-(3-methyl-butoxy)-benzoyl]-benzenesulfonamide 
• 1189545-72-9 2-chloro-5-{hydroxy-[4-(3-methyl-butoxy)-phenyl]-methyl}-benzenesulfonamide 

Relevant articles and documents

N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof

The invention provides an N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof. The N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative comprises anoptical isomer and pharmaceutically acceptable salt thereof. Preliminary pharmacodynamic indication shows that the compound disclosed by the invention has FLT3 inhibitory activity, wherein the proliferation inhibition activity is realized on various leukemia cell strains; moreover, the derivative is effective for multiple mutations of AML, such as internal tandem repeat mutation of a near-membranestructural domain and D835 point mutation of an activated ring in a kinase structural domain and almost has no inhibition effect on c-KIT. The derivative can overcome drug resistance brought by clinical point mutation, can reduce toxic and side effects of bone marrow inhibition, and can be applied to preparation of antitumor drugs. The general structural formula of the derivative is shown in thespecification.